Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Asset Writedowns and Impairment: 2009-2024

Historic Asset Writedowns and Impairment for Amicus Therapeutics (FOLD) over the last 7 years, with Dec 2024 value amounting to $9.2 million.

  • Amicus Therapeutics' Asset Writedowns and Impairment fell 59.49% to $367,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $9.0 million, marking a year-over-year decrease of 98.10%. This contributed to the annual value of $9.2 million for FY2024, which is 237.73% up from last year.
  • Amicus Therapeutics' Asset Writedowns and Impairment amounted to $9.2 million in FY2024, which was up 237.73% from $2.7 million recorded in FY2023.
  • Over the past 5 years, Amicus Therapeutics' Asset Writedowns and Impairment peaked at $18.2 million during FY2022, and registered a low of $99,000 during FY2020.
  • Over the past 3 years, Amicus Therapeutics' median Asset Writedowns and Impairment value was $9.2 million (recorded in 2024), while the average stood at $10.0 million.
  • Per our database at Business Quant, Amicus Therapeutics' Asset Writedowns and Impairment tumbled by 85.00% in 2023 and then spiked by 237.73% in 2024.
  • Yearly analysis of 4 years shows Amicus Therapeutics' Asset Writedowns and Impairment stood at $99,000 in 2020, then reached $18.2 million in 2022, then crashed by 85.00% to $2.7 million in 2023, then spiked by 237.73% to $9.2 million in 2024.